YARDLEY, PA — Red Nucleus has acquired Bridge Medical Consulting, a specialized health economics and outcomes research consultancy, in a move that deepens the company’s capabilities as biopharmaceutical firms face intensifying scrutiny over drug pricing, reimbursement and clinical value.
The acquisition strengthens Red Nucleus’s position in the rapidly evolving health economics and outcomes research, or HEOR, sector — a discipline increasingly central to how therapies are evaluated by regulators and payers worldwide.
Founded in 2011, Bridge Medical Consulting has built a reputation for scientific rigor in evidence synthesis, integrated evidence planning, population insights, economic modeling and statistical analysis. The firm works with pharmaceutical and biotechnology companies across Europe and the United States, combining domain expertise with artificial intelligence–enabled workflows to deliver research at speed and scale.
“With payers and regulators placing unprecedented scrutiny on drug pricing and value, HEOR has become mission-critical for life sciences companies,” said Mike Menta, chief executive officer of Red Nucleus. “This acquisition enhances our ability to support clients across value, evidence, and market access. Bridge Medical Consulting’s expertise, culture, and forward-looking approach to technology make them an exceptional fit for Red Nucleus, and we’re excited to welcome their team.”
The combined organization will offer an expanded portfolio of services spanning systematic literature reviews, indirect treatment comparisons, evidence planning and generation, real-world evidence research, economic modeling, statistical analysis and strategic advisory. Company leaders said the move positions Red Nucleus to help clients navigate evolving global requirements, including increased demand for real-world evidence and joint clinical assessments in Europe.
Paul Gandhi, founder and chief executive officer of Bridge Medical Consulting, said the integration allows the firm to broaden its reach while maintaining its focus on methodological integrity.
“Joining Red Nucleus allows us to scale our impact and offer clients a broader, more integrated set of services,” Gandhi said. “We share a commitment to scientific excellence and to thoughtfully applying AI and related technologies to enhance rigor and efficiency, while keeping expert judgment at the center of our work.”
Bridge Medical Consulting will merge with Red Nucleus’s existing HEOR division under Monique Martin, global head of HEOR. Martin described the partnership as a natural alignment of complementary strengths.
“I have been particularly impressed by their robust and transparent approach to developing applied AI solutions, especially to decision-grade SLRs, combining the best of AI with the best of humans to yield the highest quality client outputs,” Martin said.
HEOR operates within Red Nucleus’s broader global Value & Evidence organization, as the company continues expanding its footprint in supporting life sciences clients navigating an increasingly complex regulatory and reimbursement landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.